Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2009 | 68 | 3 |
Tytuł artykułu

Morphometric and immunohistochemical study of angiogenic marker expressions in invasive ductal carcinomas of the human breast

Warianty tytułu
Języki publikacji
Breast cancer is the leading cause of cancer deaths among women. Results from experimental studies suggest that tumour progression and metastasis in breast cancer are angiogenesis dependant. The College of American Pathologists has stated that further study of quantification of tumour angiogenesis is still required to demonstrate its prognostic value in breast cancer. In this study, not only the microvascular density (MVD), but also the vascular area ratio (VAR), and the vascular count in different grades of invasive ductal breast carcinoma were assessed using a pan-endothelial marker, CD34, and monoclonal antibody to CD105, by employing computer assisted morphometric measurements. In addition, quantitative expression of vascular endothelial growth factor (VEGF) was detected. Correlation of the vascular parameters and VEGF expression with the different grades of invasive ductal breast carcinoma was clarified. Immunohistochemical staining for the CD105, CD34, and VEGF antibodies were performed in 25 patients with invasive ductal carcinoma in King Fahd Hospital, Saudi Arabia. Normal breast tissue samples comprised 15 specimens detected at the safety margin of the malignant breast cases were collected. Positive CD34 stained blood-vessel endothelial cells were observed in all normal breast tissues. In contrast, CD105 and VEGF expression were not expressed in the normal breast ducts and lobules. Widespread staining for CD34, to a lesser extent CD105, and VEGF expression were seen in all tumour specimens with different grades. Significant differences in the vascular parameters, stained with antiCD34, were observed between normal breast tissues and invasive ductal carcinoma. In addition, the vascular parameters stained with antiCD34 and antiCD105, and the percentage of VEGF expression in the three grades of invasive ductal carcinomas showed significant differences with positive correlations. In conclusion, MVD as well as VAR are considered to reflect the final result of the tumour angiogenesis cascade. In addition, VEGF expression was found to be a useful angiogenic marker. However, few cases were VEGF negatively stained. Thus, the expression of MVD, VAR, and to a lesser extent VEGF might be reference predictors for the biological behaviour and prognosis of breast carcinoma. (Folia Morphol 2009; 68, 3: 144–155)
Słowa kluczowe
Opis fizyczny
  • Faculty of Medicine Anatomy, Al-Madinah Al-Monwarah, Saudi Arabia
  • Faculty of Medicine Obstetrics and Gynaecology, Al-Madinah Al-Monwarah, Saudi Arabia
  • Faculty of Medicine Anatomy, Al-Madinah Al-Monwarah, Saudi Arabia
  • Faculty of Medicine Pathology, Al-Madinah Al-Monwarah, Saudi Arabia
  • Faculty of Medicine Surgery, Al-Madinah Al-Monwarah, Saudi Arabia
  • Faculty of Medicine Anatomy, Al-Madinah Al-Monwarah, Saudi Arabia
  • 1. Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, Cairnduff F, Selby PJ, Perren TJ, Lansdown M, Banks RE (2000) Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res, 60: 2898–905.
  • 2. Al-Harris ES, Al-Janabi AA, Al-Toriahi KM, Yasseen AA (2008) Over expression of vascular endothelial growth factor in correlation to Ki-67, grade, and stage of breast cancer. Saudi Med J, 29: 1099–1104.
  • 3. Beresford MJ, AL Harris ES, Ah-See M, Daley F, Padhani AR, Makris A (2006) The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. Br J Cancer, 95: 1683–1688.
  • 4. Bocci G, Fasciani A, Danesi R, Viacava P, Genazzani AR, Del Tacca M (2001) In-vitro evidence of autocrine secretion of vascular endothelial growth factor by endothelial cells from human placental blood vessels. Mol Hum Reprod, 7: 771–777.
  • 5. Bolat F, Kayaselcuk F, Nursal TZ, Yagmurdur MC, Bal N, Demirhan B (2006) Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. J Exp Clin Cancer Res, 25: 365–372.
  • 6. Brekken RA, Li C, Kumar S (2002) Strategies for vascular targeting in tumours. Int J Cancer, 100: 123–130.
  • 7. Brewer CA, Setterdahl JJ, Li MJ, Johnston JM, Mann JL, Mcasey ME (2000) Endoglin expression as a measure of microvessel density in cervical cancer. Obstetrics Gynecol, 96: 224–228.
  • 8. Callagy G, Dimitriadis E, Harmey J, Bouchier-Hayes D, Leader M, Kay E (2000) Immunohistochemical measurement of tumor vascular endothelial growth factor in breast cancer. A more reliable predictor of tumor stage than microvessel density or serum vascular endothelial growth factor. Appl Immurvival nohistochem Mol Morphol, 8: 104–109.
  • 9. Charpin C, Dales JP, Garcia S, Carpentier S, Djemli A, Andrac L, LavautMN, Allasia C, Bonnier P (2004) Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays. Clin Cancer Res, 10: 5815–5819.
  • 10. Charpin-Taranger C, Dales JP, Garcia S, Andrac-Meyer L, Ramuz O, Carpentier-Meunier S, Bonnier P (2003) The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers. Bull Acad Natl Med, 187: 1129–1145.
  • 11. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Charpin C (2004) Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. Hum Pathol, 35: 176–183.
  • 12. Ding S, Li C, Lin S, Yang Y, Liu D, Han Y, Zhang Y, Li L, Zhou L, Kumar S (2003) Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Human Pathol, 37: 861–866.
  • 13. Dromain C, Balleyguier C, Muller S, Mathieu MC, Rochard F, Opolon P, Sigal R (2006) Evaluation of tumor angiogenesis of breast carcinoma using contrastenhanced digital mammography. Am J Roentg, 187: W528–W537.
  • 14. Du JR, Jiang Y, Zhang YM, Fu H (2003) Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinomas. World J Gastroenterol, 9: 1604–1606.
  • 15. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 19: 403–410.
  • 16. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med, 9: 669–676.
  • 17. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American pathologists consensus statement. Arch Pathol Lab Med, 124: 966–978.
  • 18. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med, 285: 1182–1186.
  • 19. Fonsatti E, Altomonte M, Nicotra MR, NataliPG, MaioM (2003) Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene, 22: 6557–6563.
  • 20. Fonsatti E, Sigalotti L, Arslan P, Altomonte M, Maio M (2003) Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets, 3: 427–432.
  • 21. Gabriel CN, Cristina BB, Arlete H, Lígia Maria BC (2008) Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas. Neuropathology, 28: 17–23.
  • 22. Gasparini G (2000) Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist, 5: 37–44.
  • 23. Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N (2005) Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer, 5: 25.
  • 24. Kohlberger P, Obermair A, Sliutz G, Heinzl H, Koelbl H, Breitenecker G, Gitsch G, Kainz C (1996) Quantitative immunohistochemistry of factor-VIII-related antigen in breast carcinoma. Am J Clin Pathol, 105: 705–710.
  • 25. Naccarato AG, Viacava P, Bocci G, Fanelli G, Aretini P, Lonobile A, Montruccoli G, Bevilacqua G (2003) Definition of the microvascular pattern of the normal human adult mammary gland. J Anat 203: 599–603.
  • 26. Nieto Y, Woods J, Nawaz F, Baron A, Jones RB, Shpall EJ, Nawaz S (2007) Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer, 97: 391–397.
  • 27. Parkin DM, Fernandez LM (2006) Use of statistics to assess the global burden of breast cancer. Breast J, 12: 70–80.
  • 28. Safwat MD, Habib FA, Oweiss NY, Bassyoni SA (2008) The microvasculature of the normal and pathological human adult mammary gland. New Egypt J Med, 38: 207–219.
  • 29. She X, Matsuno F, Haradan N, Tsai H, Seon BK (2004) Synergy between anti-endolgin (CD 105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. Int J Cancer, 108: 251–257.
  • 30. Simpson JF, Ahn C, Battifora H, Esteban JM (1996) Endothelial area as a prognostic indicator for invasive breast carcinoma. Cancer, 77: 2077–2085.
  • 31. Tafuri LSA, Rocha GFS, Gobbi H (2006) Cell cycle related proteins in hyperplasia of usual type in breast specimens of patients with and without breast cancer. BMC Cell Biol, 7: 29.
  • 32. Teo NB, Shoker BS, Jarvis C, Martin L, Sloane JP, Holcombe C (2002) Vascular density and phenotype around ductal carcinoma in situ (DCIS) of the breast. Br J Cancer, 86: 905–911.
  • 33. Uzzan B, Nicolas P, Cucherat M, Perret GY (2004) Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res, 64: 2941–2955.
  • 34. Viacava P, Gasperi M, Acerbi G, Manetti L, Cecconi E, Naccarato AF (2003) Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest, 26: 23–28.
  • 35. Viacava P, Naccarato AG, Bocci G, Fanelli G, Aretini P, Lonobile A, Evangelista G, Montruccoli G, Bevilacqua G (2004) Angiogenesis and VEGF expression in preinvasive lesions of the human breast. J Pathol, 204: 140–146.
  • 36. Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD (1993) A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer, 54: 363–370.
  • 37. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis — correlation in invasive breast carcinoma. N Engl J Med, 324: 1–8.
  • 38. Wei-guo X, Gang W, Yu-huan Z, Ji-ning S, Xiao-qing Y, Wen-ya W (2007) Vascular endothelial growth factor expression in invasive ductal carcinoma of breast. Chin J Cancer Res, 19: 56–59.
  • 39. Yang LY, Lu WQ, Huang GW, Wang W (2006) Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer, 6: 110–108.
  • 40. Yasukawa T, Kimura H, Tabata Y, Miyamoto H, Honda Y, Ikada Y, Ogura Y (2000) Active drug targeting with immunoconjugates to choroidal neovascularization. Curr Eye Res, 21: 952–961.
  • 41. Zhou S, Wang GP, Liu C, Zhou M (2006) Eukaryotic Initiation Factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer. BMC Cancer, 6: 231.
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.